 designs for health® Australia

casi

Clinical Applications of Scientific Innovation



Annatto Tocotrienol & Geranylgeraniol

Ancient Phytonutrients for Modern Day Intervention

Barrie Tan, PhD

Annatto Tocotrienol & Geranylgeraniol

Ancient Phytonutrients for Modern Day Intervention

Barrie Tan, Ph.D.

American River Nutrition, President
Designs for Health, CSO

Presented at CASI, October 22nd, 2022



Disclaimers

- This presentation is intended for educational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are solely those of Dr. Barrie Tan and derived from published studies.
- For Practitioner Use Only. This content is not medical advice. These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease.

CASI Disclosure & Preamble

- These are based on clinical studies, not medical recommendations
- Trials (18-20) on pure T3, Delta-T3, Annatto T3 were all done with ARN's DeltaGold[®]; the only company in US making T3
- A new day for GG; ARN is the first (and only) in the world to make Annatto GG as GG-Gold[®]
- Human dosages are provided throughout; if animal studies, a 70kg human translation is shown
- Most studies were done in the last 5 years.

Roadmap

- Annatto History
- Vitamin E Background
- Tocotrienol (T3) Benefits
- Geranylgeraniol (GG) Background
- Geranylgeraniol Benefits
- Summary





My Discovery Story

1. Palm Tocotrienol

- **1980s** in Malaysia
- Visit to a palm plantation

2. Rice Tocotrienol

- **1990s** in Thailand
- Call from a Prince of Thailand

3. Annatto Tocotrienol

- **2000s** in Peru
- Search for giant marigolds

4. Staying with Annatto T3 & GG

- **2010s** in USA
- Production and clinical trials

Annatto – “One Plant Wonder” from Amazonia

- Native to tropical Central & South America
- Ancient shrub of indigenous people
- Ingredient Responsibility:
 - Bixin (attractant)
 - Tocotrienol (protectant)
 - Terpenoids (repellant)




Vitamin E: A Century of Research



1922: Fetal reabsorption prevention




1937: Antioxidant properties




1964: Tocotrienol discovered



2003: Annatto T3 first in commerce



2022: Continued rise of T3 research




Structure – 8 Distinct Vitamers

Tocopherol (T)



- Alpha T
- Beta T
- Delta T
- Gamma T


Tocotrienol (T3)




- Alpha T3
- Beta T3
- Delta T3
- Gamma T3

- Most supplements are filled with tocopherols
 - Annatto is uniquely tocotrienols

Annatto Tocotrienol



- Plant-based
- Physical process
- Made in USA



- Only 3 sources (Rice, Palm, Annatto)
- Annatto is the most potent tocotrienol

So why not Alpha-Tocopherol?

Alpha-Tocopherol Interferes with Tocotrienol

- Inhibits absorption
- Reduces adipose storage
- Compromises cholesterol and triglyceride reduction
- Attenuates cancer inhibition
- Exacerbates stroke injury

Alpha-Tocopherol Problems in Physiological Functions

- Oxidizes 'good' HDL and 'bad' LDL (50mg/d & 400mg/d)
- Increases inflammation of TNF_{α} (13–40%↑) & IL_6 (21–22%↑)
- Raises mortality and cancers (breast, prostate, lung)
- Blocks/Lowers chemo's effectiveness (400mg/d for 1 mth)
- Increases cardiac risk in PMW (300mg/d for ~3yr)

Alpha-T puts **brakes** on T3 functions

Alpha-T has too many **land mines**



Recap

- Tocotrienol is a **recent** discovery
- Vitamin E = 4 tocotrienols and 4 tocopherols
- Annatto is the **most potent** source of tocotrienol
 - Alpha-tocopherol **interferes** with tocotrienol
 - Alpha-tocopherol **is laden** with land mines



Cardiovascular Disease (CVD)

Inflammation

Lipids & Oxidation

Atherosclerosis

Annatto T3 in Preclinical Hypercholesterolemia Study

Lipid (mmol/L)	Control (2% chol. in feed)	T3 Treatment	% Change	Remarks
Cholesterol	31.5	22.8	27.6%↓	<ul style="list-style-type: none"> T3 targets the down-regulation of HMGR enzyme Neat drop because of alpha-T absence*
LDL	27.7	19.5	29.6%↓	
HDL	2.58	2.68	3.9%↑	<ul style="list-style-type: none"> HDL and TG trend well with MetS control
TG	1.61	1.41	12.4%↓	
TG/HDL	0.624	0.526	15.7%↓	<ul style="list-style-type: none"> Predicts small dense LDL drop


- Animal dosage translates to **135 mg/d** in a 70kg person
- Findings justify a clinical study to validate lipid findings

Shahid U, Khan DA, Noor U, Butt SH. Effect of tocotrienols on lipid profile in rabbits. JRM. 2012;16(1):68-9.

*Hasselwander O, Kraemer K, Hoppe PP, Oberfrank U, Baldenius K, Schroeder H, et al. Effects of feeding various tocotrienol sources on plasma lipids and aortic atherosclerotic lesions in cholesterol-fed rabbits. Food Res Int'l. 2002;35:245-51.

*Yu SG, Thomas AM, Gapor A, Tan B, Qureshi N, Qureshi AA. Dose-response impact of various tocotrienols on serum lipid parameters in 5-week-old female chickens. Lipids. 2006;41(5):453-61.

For Practitioner Use Only. This content is not medical advice. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.



The human body contains
**30,000 miles
of arteries**

1.2 x the circumference of the earth


or

10 x the distance from NY to LA

Arteries carry blood cells to
import oxygen & nutrients and to
export carbon dioxide & wastes to


38 trillion cells

Tocotrienol Reduces Chemotaxis & Atherosclerosis



T3 Reduces “Velcro Effect” in arteries

- Inflammation Marker ↓
- Adhesion Molecules ↓
- Proteolytic Enzymes ↓




24% ↓

Translated dosage for a 70kg person:
340mg/day

36% ↓

Tocotrienol Reduces Cholesterol & Inflammation in Hypercholesterolemic Subjects




250mg/d

TC: 15% ↓

LDL: 18% ↓

TG: 14% ↓



250mg/d & 500mg/d


CRP: 40% ↓

MDA 34% ↓

TAS: 22% ↑

Phase duration (4 wk) and washout (2wk)

Tocotrienol Improves Markers in Hypercholesterolemic Subjects



- Reduces inflammation (CRP↓)
- Reduces lipid oxidation (MDA↓)
- Improves liver and heart functions (GGT↓)




Cardiometabolic Disease (CMD)

NAFLD


Pre-Diabetes (MetS/IR)

T2DM




CMD – A Population Code Blue

Strongest Markers (BMI↑, FBG↑ or A1c↑)



Strong Markers (BP↑, Lipids↓)



- 1-in-14 (<7%) adults have optimal CM health
- MetS↑ from 36% to 47%; highest in Mexican American (52%)
- Higher in older (>65yr) than younger (20-34) adults; 78% vs 23%

Annatto Tocotrienol and Polyphenol Combo in Healthy Elderly

Marker	Before	After	% Change	Remarks
GGT (U/L)*	26	21	19%↓	Ox. stress/heart failure markers dropped
CRP (mg/L) ¹	2.1	1.4	33%↓	Inflammation marker reduced
TAS (mmol/L)	1.45	1.61	11%↑	Endogenous antioxidant status improved

- Healthy men & women (60-67yo) for 4 weeks
- Combo (Tocotrienol **200mg/d**, Quercetin **300mg/d** and Resveratrol **100mg/d**)

Khan DA, Mahjabeen W, Khan FA. Effects of delta-tocotrienol and polyphenol on ageing induced oxidative stress and inflammation in humans. Pakistan J Path. 2009;55-9.

*Dhingra R, Gona P, Wang TJ, Fox CS, D'Agostino RB, Sr., Vasan RS. Serum gamma-glutamyl transferase and risk of heart failure in the community. Arterioscler Thromb Vasc Biol. 2010;30(9):1855-60. Epub 2010/06/12


*Onur S, Niklowitz P, Jacobs G, Nothlings U, Lieb W, Menke T, et al. Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans. BMC research notes. 2014;7:427. Epub 2014/07/06.

¹ Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circ Res. 2016;118(1):145-56. Epub 2016/02/04.

¹ Ridker PM. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week. Journal of the American College of Cardiology. 2018;72(25):3320-31. Epub 2018/11/13.


For Practitioner Use Only. This content is not medical advice. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Global NAFLD Prevalence is 20-30%



- 90-100m Americans have NAFLD (30% of adults)
- 20% transition to non-alcoholic steatohepatitis (NASH)
- Complications: Inflammation, Fibrosis, Infections, Cancer

Livers look like those of heavy drinkers but they are not



Das, S.L., et al., *Newly diagnosed diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis.* Gut, 2013.
Gukovsky, I., et al., *Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer.* Gastroenterology, 2013. 144(6): p. 1199-209 e4.
Fiore, K. *Losing Fatty Liver Cuts Diabetes Risk.* MedPage Today 2013.
Le, M., Devaki, P., Ha, N., Jun, D., Te, H., Cheung, R. and Nguyen, M. (2017). *Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States.* PLOS. Available from: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0173499>.
Estes, C., Razavi, H., Loomba, R., Younossi, Z. and Sanyal, A. (2018). *"Modeling the Epidemic of Nonalcoholic Fatty Liver Disease Demonstrates an Exponential Increase in Burden of Disease."* Hepatology, 67(1).
For Practitioner Use Only. This content is not medical advice. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Delta-Tocotrienol Improves Fatty Liver in NAFLD Patients

Three RDBPC trials in patients (80-100) on **300mg twice daily**


Study Parameters		3 mth*	6 mth ⁺	12 mth [^]
Patient	Weight Loss (lb)	10	15	11
	BMI (kg/m ²)	30.7 → 29.2	30.6 → 28.3	32.8 → 31.1
	Waist Circumference (cm)	100.2 → 98.0	100.4 → 97.5	106.5 → 102.5
HP & Doctors	Triglycerides	9.9%↓	13% ↓	16%↓
	ALT & AST	15% - 16%↓	18% - 21%↓	29%↓
	ALP & GGT	8% - 17%↓	17%↓	37%↓
	hsCRP	18%↓	21%↓	38%↓
	MDA	14%↓	19%↓	13%↓
Specialists	FIB-4, NFS (fibrosis)	-----	11.4%↓	20.1%↓
	CK18 (cirrhosis, liver cell death)	-----	18.3%↓	19.8%↓
	FLI (steatosis)	11.1%↓	15%↓	17%↓
	HOMA-IR homeostatic model assessment of insulin resistance	-----	15%↓	24%↓

*Pervez MA, Khan DA, Ijaz A, Khan S. Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology. 2018;29(2):170-6. Epub 2018/05/12.

+ Pervez, Muhammad Amjad, et al. "Delta-Tocotrienol Supplementation Improves Biochemical Markers of Hepatocellular Injury and Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized, Placebo-Controlled Trial." Complementary Therapies in Medicine, vol. 52, 2020, p. 102494., doi:10.1016/j.ctim.2020.102494.

^ Pervez MA, Khan DA, Ijaz A, Khan S. Delta-tocotrienol supplementation improves biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled trial. Complement Ther Med. 2020 Aug;52:102494.

Delta-Tocotrienol Sustains Weight Loss in NAFLD Patients




Delta-Tocotrienol Improves Glycemic Control in Prediabetics

- Clinical Trial
 - RDBPC, 3mth, DeltaGold® **300mg/day**
 - 77 prediabetic patients (FPG 100-124mg/dl; A1c 5.7-6.4%)

	T3-Supplemented	Placebo
A1C	6.04 → 5.77% (4.5%↓)	5.99 → 6.04% (0.8%↑)
FPG	4.3%↓	0.2%↓
Insulin	11.2%↓	3.0%↓
HOMA-IR	15.1%↓	3.7%↓

Delta-Tocotrienol Averts Pre-D-to-T2DM Conversion



- CDC says progression of A1c-confirmed PreD-to-T2DM is **5.3%** in older adults
- US has **95m** Pre-diabetics
- APR approximates BMI

Window of opportunity (green section)

Evidence of T3 in PreD-to-T2DM non-progression

Non Reversion of MetS and Central Obesity

Combo (**Delta-T3 500mg/d + Resveratrol 300mg/d**) for 6mth on MetS patients

Primary Endpoints:

SBP/DBP (5.2%/5.8%↓)
WC ♂ / ♀ (3.7%/4.6%↓)
Weight Loss (4.6% or 9.3lb↓)
TG (16%↓)
HDL ♂ / ♀ (4.0%/5.1%↑)

Secondary Endpoints:

Inflammation (15-17%↓)
Adiponectin (11%↑)
VCAM (27%↓)
MDA (7.5%↓)
TAS (23%↑)

Conclusions of (Delta-T3 + Resveratrol) Combo:

- Reversed MetS & Central Obesity (40%) and Metabolites (55%)
- Decreased Relative Risk of reversion to MetS & Central Obesity (both by 70%)
- Improved MetS of young adults (18-43yr)

Delta-Tocotrienol Helps T2DM Patients

Randomized, double-blind, placebo-controlled trials
6mth study with 60-110 patients

Study Parameters	Results (250mg/d)	Results (500mg/d)
Glucose	6.8%↓	7%↓
HbA1c	6.3%↓	8%↓
Insulin	7.6%↓	9%↓
HOMA-IR	13.1%↓	14%↓
Triglycerides	10.3%↓	8%↓
hsCRP	10.1%↓	12%↓
IL-6	15.9%↓	9%↓
TNF-alpha	13.7%↓	14%↓
MDA	8.8%↓	11%↓

Mahjabeen, W., et al. (2021). "Effects of delta-tocotrienol supplementation on Glycemic Control, oxidative stress, inflammatory biomarkers and miRNA expression in type 2 diabetes mellitus: A randomized control trial." *Phytother Res.*

Qureshi, A. A., et al. (2021). "A Novel Mixture of δ -Tocotrienol, Vitamin D3, Resveratrol (NS-3) Significantly Decreases Diabetes Biomarkers Including Inflammatory in People with Type 2 Diabetes." *J Diab Clin Stud* 5(1).

Values not adjusted against placebo

For Practitioner Use Only. This content is not medical advice. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.



Bone Health

Many Animal Studies
One Clinical Trial

Preclinical studies conclude that annatto tocotrienols...

- Ovariectomized model – for women > 45 years
- Orchiectomized model – for men > 65 years
- HFHC diet (MetS & OP) model – both men & women
- Cigarette smoke & nicotine – toxicant induced
- Chronic steroid medicines – drug induced
- Fractured bone model – healing process

... promote bone formation following excessive resorption.

Chin, K.Y. and S. Ima-Nirwana, Effects of annatto-derived tocotrienol supplementation on osteoporosis induced by testosterone deficiency in rats. *Clin Interv Aging*, 2014. 9: p. 1247-59.

Chin, K.Y., et al., annatto tocotrienol improves indices of bone static histomorphometry in osteoporosis due to testosterone deficiency in rats. *Nutrients*, 2014. 6(11): p. 4974-83.

Abdul-Majeed, S., N. Mohamed, and I.N. Soelaiman, Effects of tocotrienol and lovastatin combination on osteoblast and osteoclast activity in estrogen-deficient osteoporosis. *Evid Based Complement Alternat Med*, 2012. 2012: p. 960742.

Ibrahim, N., et al., Targeted delivery of lovastatin and tocotrienol to fracture site promotes fracture healing in osteoporosis model: micro-computed tomography and biomechanical evaluation. *PLoS One*, 2014. 9(12): p. e115595.

Wong SK, Chin KY, Suhaimi FH, Ahmad F, Ima-Nirwana S. Exploring the potential of tocotrienol from *Bixa orellana* as a single agent targeting metabolic syndrome and bone loss. *Bone*. 2018;116:8-21. Epub 2018/07/11.


Shen CL, Kaur G, Wanders D, Sharma S, Tomison MD, Ramalingam L, et al. annatto-extracted tocotrienols improve glucose homeostasis and bone properties in high-fat diet-induced type 2 diabetic mice by decreasing the inflammatory response. *Scientific reports*. 2018;8(1):11377.

Epub 2018/07/29.

For Practitioner Use Only. This content is not medical advice. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.




Intro to Bone Health

- Osteoblasts
 - Make up new bone
 - Produce collagen matrix [for structural framework]
- Osteoclasts
 - Break down old bone
 - Produce acids & enzymes [to dissolve minerals & protein]
- Menopause (45-55yo)
 - Estrogen↓ → Oxidative stress↑
- Oxidative Stress causes
 - Osteoblastic disruption → Formation↓
 - Osteoclastic differentiation → Resorption↑



Superimposition of Estradiol & Tocotrienol Structures

Tocotrienol Aids Mineralization in Fracture and MetS



- Prevented fracture recurrence, increased callus stiffness
- Improved trabecular bone microstructure and bone strength
- Increased osteoblast surface
- Improved metabolic syndrome parameters

70kg human equivalent dose: **680mg/day**

Chin, K.Y. and S. Ima-Nirwana, Effects of annatto-derived tocotrienol supplementation on osteoporosis induced by testosterone deficiency in rats. Clin Interv Aging, 2014. 9: p. 1247-59.

Chin, K.Y., et al., annatto tocotrienol improves indices of bone static histomorphometry in osteoporosis due to testosterone deficiency in rats. Nutrients, 2014. 6(11): p. 4974-83.

Wong SK, Chin KY, Suhaimi FH, Ahmad F, Ima-Nirwana S. Exploring the potential of tocotrienol from Bixa orellana as a single agent targeting metabolic syndrome and bone loss. Bone. 2018;116:8-21. Epub 2018/07/11.


Shen CL, Kaur G, Wanders D, Sharma S, Tomison MD, Ramalingam L, et al. annatto-extracted tocotrienols improve glucose homeostasis and bone properties in high-fat diet-induced type 2 diabetic mice by decreasing the inflammatory response. Scientific reports. 2018;8(1):11377. Epub 2018/07/29.

Ibrahim, N., et al., Targeted delivery of lovastatin and tocotrienol to fracture site promotes fracture healing in osteoporosis model: micro-computed tomography and biomechanical evaluation. PLoS One, 2014. 9(12): p. e115595.

For Practitioner Use Only. This content is not medical advice. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

First Annatto Tocotrienol Bone Clinical Trial

- PMW in 3 treatments for 12 wks (placebo, **300mg/d** and **600mg/d**)
- Benefits to PMW at 300mg/d are:
 - Bone building (BALP/NTX) - 115%↑
 - Bone resorption (sRANKL/OPG) - 13%↓
 - Oxidative stress (8-OHdG) - 49%↓



- No adverse effects on liver and kidney function or quality of life
- PMW obesity trial for 24 wks (placebo and **300mg/d** T3)

DeltaGold® Tocotrienol Summaries

- Annatto tocotrienol is the most potent anti-inflammatory vitamin E
 - Decreases lipid oxidation and atherosclerosis in CVD
- Balances metabolites and reduces markers in CMD
- Mitigates steatosis and fibrosis in NAFLD/NASH; WC/BMI/Weight loss
 - Prevents osteopenia and obesity
- Recommended Dosage (with meal)
 - Healthy: 100-300mg/day
 - Mild Chronic Condition: 300-400mg/day
 - Advanced Chronic Condition: 400-600mg/day





Geranylgeraniol

Introduction

Benefits

Summary


GG is a Building Block in **Plant** & **Mammal**

Essential:

- Growth and differentiation
- Apoptosis and survival

Endogenous:

- Plants and mammals
- For all stages of life



Nakagawa K, Hirota Y, Sawada N, Yuge N, Watanabe M, Uchino Y, et al. Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme. *Nature*. 2010;468(7320):117-21. Epub 2010/10/19.


Hirota Y, Nakagawa K, Sawada N, Okuda N, Sahara Y, Uchino Y, et al. Functional characterization of the vitamin K2 biosynthetic enzyme UBIAD1. *PLoS one*. 2015;10(4):e0125737. Epub 2015/04/16.

Huang H, Levin EJ, Liu S, Bai Y, Lockless SW, Zhou M. Structure of a membrane-embedded prenyltransferase homologous to UBIAD1. *PLoS biology*. 2014;12(7):e1001911. Epub 2014/07/23.


For Practitioner Use Only. This content is not medical advice. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Ubiquity and Bioavailability of GG


MK4 and CoQ10 are ubiquitous because GG is ubiquitous



Vitamin K2 (MK4)
[1 GG]



CoQ10
[2.5 GG]




CoQ10 (MW863)


Difficult to absorb & get into membranes
Largest of the “small molecules”

GG (MW290)

Easy to absorb into cellular membranes
Smallest of the “small molecules”



GG is Central to Mevalonate Pathway




C. Buettner et al. Statin-Induced Myopathy and its Management, Fig. 1. CML – Rheumatology 2010;29(4):105–19.

B Tan, F. Rosenfeldt, et al. Evidence and Mechanisms for Statin-induced Cognitive Decline. Exp. Rev. Clin. Pharmacol. 2019;12(5):391–406.

Hooff GP, Wood WG, Muller WE, Eckert GP. Isoprenoids, small GTPases and Alzheimer's disease. Biochim Biophys Acta. 2010;1801(8):896–905. Epub 2010/04/13.

For Practitioner Use Only. This content is not medical advice. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

GG is Easily Blocked in the Mevalonate Pathway



C. Buettner et al. Statin-Induced Myopathy and its Management, Fig. 1. CML – Rheumatology 2010;29(4):105–19.

B Tan, F. Rosenfeldt, et al. Evidence and Mechanisms for Statin-induced Cognitive Decline. Exp. Rev. Clin. Pharmacol. 2019;12(5):391-406.

Hooff GP, Wood WG, Muller WE, Eckert GP. Isoprenoids, small GTPases and Alzheimer's disease. Biochim Biophys Acta. 2010;1801(8):896-905. Epub 2010/04/13.

For Practitioner Use Only. This content is not medical advice. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.



GG Benefits



Protein Synthesis

Testosterone, CoQ10 & MK4 Synthesis

Increase in Bone Strength

Mitigation of Drug Side Effects


Protein Synthesis



- Radiolabeled GG was found within protein fractions
- Clinical significance of protein synthesis:
 - **Myopathy** (drug-related); statins & bisphosphonates; typically >30yr old
 - **Sarcopenia** (age-related); 40yr and older

- Proteins with GG (1-2%) requirements:
 - Rho – ATP/energy production
 - Rab – Membrane/signaling protein (GG acts as anchor)
 - Rac – Regulation of cell movement (cytoskeleton & muscle)

Hormone Synthesis & GG



- Leopold Ruzicka: 1939 Nobel Prize for testosterone and GG synthesis
- GG stimulates steroid synthesis of both Testosterone and Progesterone[‡]
 - Mechanism of GG involvement yet unknown
 - Potentially due to GG-MK4 synthesis

*Leopold Ruzicka – Facts. NobelPrize.org. Nobel Media AB 2020. Tue. 7 Apr 2020. <https://www.nobelprize.org/prizes/chemistry/1939/ruzicka/facts/>

Ruzicka L, Firmenich G. Zur Kenntnis der Diterpene (37. Mitteilung). Synthese des aliphatischen Diterpenalkohols Geranyl-geraniol. Helv. 1939;22(1):392-396. (This one if Barrie wants to make reference to Ruzicka being the first to synthesize GG)


[‡]Ho HJ, Shirakawa H, Giriwono PE, Ito A, Komai M. A novel function of geranylgeraniol in regulating testosterone production. Bioscience, biotechnology, and biochemistry. Jun 2018;82(6):956-962.

[‡]Ho HJ, Shirakawa H, Yoshida R, et al. Geranylgeraniol enhances testosterone production via the cAMP/protein kinase A pathway in testis-derived I-10 tumor cells. Bioscience, biotechnology, and biochemistry. 2016;80(4):791-797.


For Practitioner Use Only. This content is not medical advice. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

GG Stimulates Testosterone (T) Synthesis


Human equivalent dose: **100mg/d**



GG supplemented diet **enhances** plasma testosterone levels in male rats



MK4 supplemented diet **enhances** testosterone production in rat testis



Ho HJ, Shirakawa H, et al. A novel function of geranylgeraniol in regulating testosterone production. *Biosci Biotechnol Biochem.* 2018; 82(6):956-962

Ito, A., Shirakawa, H., Takumi, N., Minegishi, Y., Ohashi, A., Howlader, Z.H., Ohsaki, Y., Sato, T., Goto, T. and Komai, M., 2011. Menaquinone-4 enhances testosterone production in rats and testis-derived tumor cells. *Lipids in health and disease*, 10(1), p.158.

Al Rajabi A, Booth SL, Peterson JW, Choi SW, Suttie JW, Shea MK, et al. Deuterium-labeled phyloquinone has tissue-specific conversion to menaquinone-4 among Fischer 344 male rats. *J Nutr.* 2012;142(5):841-5. Epub 2012/03/23.

Nakagawa, Kimie, et al. Identification of UBIAD1 as a novel human menaquinone – 4 biosynthetic enzyme. *Nature.* 11/4/2010; 468, 117-121.


For Practitioner Use Only. This content is not medical advice. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

GG Reduces Bone Resorption & Synthesizes Vitamin K2



The inhibitory effect of vitamin K₂ on bone resorption may be related to its side chain (1995) and this GG → MK4 was proven (2010-2013)

- GG → vitamin K₂; MK4 is an endogenous nutrient
- GG inhibited bone resorption similarly to vitamin K₂
- Human equivalent dose = **160mg/d**



Nakagawa K, et al. Identification of UBIAD1 as a novel human MK4 biosynthetic enzyme. *Nature* (Nov 4, 2010) 468, 117-121.

Hirota Y, et al. Menadione (Vitamin K3) is a catabolic product of oral phylloquinone (Vitamin K1) in the intestine and circulating precursor of tissue menaquinone4 (vitamin K2) *Jbiol. Chem.* (Nov 15, 2013) 288, (46) 33071-33080.

Rajabi AA, et al. Deuterium-labeled phylloquinone has tissue-specific conversion menaquinone 4 among Fischer 344 male rats. *J Nutr.* (March 21, 2012) 142, 841-845.




Hara K, Akiyama Y, Nakamura T, Murota S, Morita I. The inhibitory effect of vitamin K2 (menatetrenone) on bone resorption may be related to its side chain. *Bone.* 1995;16(2):179-84. *Epub* 1995/02/01.

Harshman SG, Shea MK, Fu X, et al. Atorvastatin Decreases Renal Menaquinone-4 Formation in C57BL/6 Male Mice. *J Nutr.* Mar 1 2019;149(3):416-421.

For Practitioner Use Only. This content is not medical advice. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.


GG Improves Bone Turnover and Increases Bone Stiffness

T2DM mouse model (osteoporosis-inducing)



- GG protected bone microstructure and quality
- GG significantly improved bone turnover
- Human equivalent dose: **160mg/day**


GG Supports Respiration and Synthesizes CoQ10



- GG reversed statins' negative impact
 - Increased mitochondrial respiration
 - Restored ubiquinone synthesis
 - Continued cholesterol reduction


GG by itself increases CoQ10 synthesis

GG Prevents Statin Myotoxicity



- Statin **stopped** a GG-step to make RAP protein
- GG **stimulated** RAP1 prenylation
- GG **reversed** statin-associated cytotoxicity
- GG **rescued** detrimental effect on myotubes

GG Restores Cells and Muscle Fibers




- Statin **destroyed** cell morphology, **interrupted** cytoskeleton synthesis
- Statin **caused** visible muscle damage
- GG **reduced** fiber damage in myotubes

GG Increases Calf Muscle Force and Soleus Muscle

Young & Healthy Rats (Control, GG, Statin, GG+Statin)

- Increased shinbone muscle force, Reversed muscle fatigue
- Improved cardiac muscle contraction/relaxation
- Statin reduced force production, GG completely abrogated this effect
- GG increased soleus muscle (30%↑) in diabetic rats
- GG supplementation mitigated soleus muscle atrophy through
 - Increased damaged organelle clearance (mitophagy↑)
 - Improved mitochondrial quality
- 70kg person: **170mg/d** and **510mg/d** of GG

GG Regenerates Aging Atrophied Muscle



- GG suppressed Atrogin-1 induced muscle atrophy
- GG increased myotube thickness
- GG increased skeletal muscle fiber size

Pleiotropic Statin Benefits **Well Beyond** a Cholesterol Reducer

- 40m Statin users may reach 80m by 2030
- Statin is the 21st Century ‘Aspirin’
- Statin will replace 52m acetaminophen users
- One-in-four patients have SAMS*
- 20m Statin users may benefit from GG

*Statin-Associated Muscle Symptoms

Orkaby, AR et al., Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older. JAMA 324 (1) 68-78, 2020.


Eldor R, Raz I, ADA Indications for Statins in Diabetes. Diabetes Care 32, S384-391, Nov 2009.

Acetaminophen by Consumer Healthcare Product Association (CHPA) 2020.

Daniels LB, Ren J, Kumar K, Bui QM, Zhang J, Zhang X, et al. (2021) Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: Findings from the American Heart Association's COVID-19 Cardiovascular Disease Registry. PLoS ONE 16(7): e0254635.


For Practitioner Use Only. This content is not medical advice. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

BisP Impacts Alveolar Bone Turnover and Necrosis



For Practitioner Use Only. This content is not medical advice. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

GG Reduces BRONJ Damage (Systemic) [2015]



Wk0 — 2wk — Wk2 — 4wk — Wk6



[ZA]
[+LPS]

Extrn
[GG]

Mice: ZA & GG (twice/wk @ 3 μ M) IP

- BMD 47% ▲ and BV/TV 28% ▲
- GG improved bone in tooth sockets
- GG restored bone deposition

GG Reduces BRONJ Damage (Systemic) [2021]



Wk0 — 1wk — Wk1 — 3wk — Wk4

[ZA]




Mice: ZA & GG (twice/wk @ 6 μ M) IP

- BMD 30% ▲ and BV/TV 15% ▲
- GG prevented jaw necrosis (2.5x)
- GG prevented gum death (3.5x)

GG Reduces BRONJ Damage (Local) [2018]




Control



ZA



ZA + GG



- ZA application **inflamed** soft tissues, **cause** bone defect by **80%**
- GG **sealed** empty lacunes (extracted sockets) by **45%**
- GG **improved** gum (vascularity, osteoblast lining, epithelial coverage) by **67%**

GG-Gold® Summaries

Take Home

- Building block & endogenous nutrient
- Synthesizes CoQ10 & MK4
- Promotes cardiovascular health
- Maintains muscle and bone strength
- Decreases with age and certain meds

Recommended Dosage (with meal)

- **150mg/day** for most applications:
 - Bone and Oral health
 - CoQ10 & MK4 replenishment
 - Muscle tone and balance
- **300mg/day:**
 - Testosterone increase
 - Statin & BisP medications
 - Myopathy & Sarcopenia

Trial 1: GG and SAMS

Effect of Annatto-Derived Geranylgeraniol (GG) on Statin-Associated Myopathy

Study Outline:

- Double-blind, placebo-controlled, randomized intervention trial
- 12 week treatment with follow-ups at 3 and 6 months post-treatment
- 75 subjects
- Three groups: **150mg/day**, **300mg/day**, Placebo
- Endpoints
 - GG reduces muscle-related symptoms (survey, pain inventory questionnaire)
 - GG improves muscle performance (muscle pain scoring, physical endurance/strength tests)
 - GG reduces muscle damage (creatinine kinase, atrogen-1, myostatin) and mitigates inflammation (CRP, IL-6)

Virani, S.S., et al., Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. *Circulation*, 2021. 143(8): p. e254-e743.

Orkaby, A.R., et al., Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older. *JAMA*, 2020. 324(1): p. 68-78.

Lansberg, P., et al., Nonadherence to statins: individualized intervention strategies outside the pill box. *Vasc Health Risk Manag*, 2018. 14: p. 91-102.

Matsubara, T., et al., Geranylgeraniol-induced Myogenic Differentiation of C2C12 Cells. *In Vivo*, 2018. 32(6): p. 1427-1431.

Miyawaki, A., et al., Oral Administration of Geranylgeraniol Rescues Denervation-induced Muscle Atrophy via Suppression of Atrogen-1. *In Vivo*, 2020. 34(5): p. 2345-2351.

Stoffel, W. and C. Martius, Zur Synthese der K-Vitamine und Ubichinone. *Angew Chem*, 1960. 72(17): p. 627-627.

Chen, Z., et al., Does statins promote vascular calcification in chronic kidney disease? *Eur J Clin Invest*, 2017. 47(2): p. 137-148.

For Practitioner Use Only. This content is not medical advice. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Trial 2: GG and Sexual Health

Effect of Geranylgeraniol (GG) Supplementation on Sexual Health in Males and Females

Study Outline:

- Unique dose escalation design
- 4 weeks on **150mg/day** vs. placebo; additional 4 weeks on **300mg/day** vs. placebo
- Total 70 patients (40 male, 30 female)
- Biomarkers studied:
 - Total, bioavailable & free testosterone
 - SHBG, estrogen, progesterone
 - Renal & hepatic panels (CBC & CMP)

Okamura, K., F. Ando, and H. Shimokata, Serum total and free testosterone level of Japanese men: a population-based study. *Int J Urol*, 2005. 12(9): p. 810-4.

Akishita, M., et al., Low testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors. *Atherosclerosis*, 2010. 210(1): p. 232-6.

Beatrice, A.M., et al., Testosterone levels and type 2 diabetes in men: current knowledge and clinical implications. *Diabetes Metab Syndr Obes*, 2014. 7: p. 481-6.

Huhtaniemi, I., Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment. *Asian J Androl*, 2014. 16(2): p. 192-202.

Ma, R.C. and P.C. Tong, Testosterone levels and cardiovascular disease. *Heart*, 2010. 96(22): p. 1787-8.

Pye, S.R., et al., Late-onset hypogonadism and mortality in aging men. *J Clin Endocrinol Metab*, 2014. 99(4): p. 1357-66.

Shores, M.M., et al., Low serum testosterone and mortality in male veterans. *Arch Intern Med*, 2006. 166(15): p. 1660-5.

Ho, H.J., et al., Geranylgeraniol enhances testosterone production via the cAMP/protein kinase A pathway in testis-derived I-10 tumor cells. *Biosci Biotechnol Biochem*, 2016. 80(4): p. 791-7.

Ho, H.J., et al., A novel function of geranylgeraniol in regulating testosterone production. *Biosci Biotechnol Biochem*, 2018. 82(6): p. 956-962.

Ito, A., et al., Menaquinone-4 enhances testosterone production in rats and testis-derived tumor cells. *Lipids Health Dis*, 2011. 10: p. 158.

For Practitioner Use Only. This content is not medical advice. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

DFH Products and Combos

- Annatto-E
- Annatto-GG
- Annatto-E GG
- CoQNoI
- Resveratrol Supreme
- PerioPull
- Tri-K
- Primal Multi



Thank You!

Book Signing and Literature at Booth

Email life@american-river.com
www.americanrivernutrition.com
333 Venture Way, Hadley, MA